Drugs / Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05735717 | May 2023 → Nov 2027 expected | CBL-related disorder, acute lymphoblastic leukemia, acute myeloid leukemia, central nervous system leukemia +6 | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05735717 ↗ |